Summary: Recent reports identify a small number of cases of Guillain-Barré syndrome (GBS) that occurred after administration of the AstraZeneca (ChAdOx1‑S) COVID-19 vaccine. Although these events appear to be very rare, clinicians and public-health surveillance systems should remain alert. The benefits of COVID-19 vaccination continue to outweigh the small potential risk of serious but uncommon adverse neurological events.
Source: Wiley
Two separate reports published in the Annals of Neurology describe a small cluster of Guillain-Barré syndrome cases that followed vaccination with the Oxford–AstraZeneca COVID-19 vaccine. The reports — one from England and one from India — highlight an uncommon GBS presentation marked by pronounced facial weakness.
In Kerala, India, clinicians identified seven patients with Guillain-Barré syndrome after a regional vaccination campaign in which roughly 1.2 million people received the AstraZeneca vaccine. In Nottingham, England, four similar cases were observed in a population where about 700,000 people had been given the same vaccine. All eleven patients developed symptoms between 10 and 22 days after receiving the vaccine.
Investigators estimated that the observed occurrence of GBS in these localities was up to ten times higher than expected for the same time frame and population size. The cases shared a notable clinical feature: a bifacial weakness with paraesthesias variant of GBS, in which bilateral facial weakness is a prominent component.
Authors of the England report note that, if a causal relationship exists, one possible mechanism could be a cross-reactive immune response to the SARS‑CoV‑2 spike protein that inadvertently affects components of the peripheral nervous system. The researchers emphasize that this explanation is speculative and that robust surveillance and careful case documentation are essential to determine causality.
Both groups of authors urge clinicians to be vigilant for signs of GBS after COVID-19 vaccination, particularly the bifacial weakness variant, and to report suspected cases promptly to local surveillance programs. Early recognition and treatment of GBS can influence clinical outcomes—several patients in the reports required intensive care support, and some received treatments such as intravenous immunoglobulin or corticosteroids while others were managed conservatively.
About this neurology research news
Source: Wiley
Contact: Press Office – Wiley
Image: The image is in the public domain
Original Research (open access): “Guillain-Barré syndrome variant occurring after SARS‑CoV‑2 vaccination” by Christopher Martin Allen et al., Annals of Neurology; “Guillain-Barré syndrome following ChAdOx1‑S/nCoV‑19 vaccine” by Boby Varkey Maramattom et al., Annals of Neurology
Abstract — Guillain-Barré syndrome variant occurring after SARS‑CoV‑2 vaccination
Although SARS‑CoV‑2 vaccines are generally very safe, the England report describes four cases of the bifacial weakness with paraesthesias variant of Guillain-Barré syndrome occurring within three weeks of vaccination with the Oxford–AstraZeneca SARS‑CoV‑2 vaccine. This rare neurological presentation has also been reported in association with SARS‑CoV‑2 infection itself. Management in the reported cases included intravenous immunoglobulin, oral steroids, or conservative observation. The authors recommend vigilance for this GBS variant following SARS‑CoV‑2 vaccination and call for comprehensive post‑vaccination surveillance to capture reliable data and assess any potential causal link.
Abstract — Guillain-Barré syndrome following ChAdOx1‑S/nCoV‑19 vaccine
Between mid‑March and mid‑April 2021 in three districts of Kerala, India, approximately 1.5 million people received COVID‑19 vaccines; more than 80% (about 1.2 million) received the ChAdOx1‑S/nCoV‑19 (AstraZeneca) vaccine. During that four‑week period clinicians observed seven cases of Guillain‑Barré syndrome that began within two weeks of the first vaccine dose. All seven patients developed severe GBS; six progressed to areflexic quadriplegia and required mechanical ventilatory support. The observed frequency of GBS in this population was estimated at 1.4 to 10 times higher than expected over the same timeframe, and the rate of bilateral facial weakness—typically seen in <20% of GBS cases—appeared higher than usual, suggesting a possible pattern worth further investigation. The authors note that, despite this rare outcome (estimated at 5.8 cases per million in their analysis), the benefits of vaccination substantially outweigh the risks, while underscoring the need for clinician awareness and continued surveillance.
Notes for clinicians and public health professionals: monitor for early signs of Guillain‑Barré syndrome after vaccination (such as progressive weakness, sensory changes, and facial weakness), document timelines accurately, and report cases to local and national surveillance systems to allow reliable assessment of frequency and possible causation. For the general public, these findings do not negate the protective value of COVID‑19 vaccination; they reinforce the importance of safety monitoring and informed clinical follow‑up when unexpected neurological symptoms occur after immunization.